BVd, belantamab mafodotin, bortezomib, and dexamethasone; DVd, daratumumab, bortezomib, and dexamethasone; HR, hazard ratio; ITT, intention to treat; NR, not reached ...

At the American Society of Clinical Oncology (ASCO) annual meeting, positive findings were presented on two phase III trials -- DREAMM-7 and DREAMM-8-- testing belantamab mafodotin (Blenrep) in ...

Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; ...

At a median follow-up of 39.4 months, results from the second interim analysis showed a sustained and significant OS benefit with BVd compared to DVd.

Learn the correct pronunciation of the Belantamab, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, warnings ...

An investigational drug with a novel mechanism of action has shown promise in the treatment of patients with relapsed/refractory multiple myeloma in a phase 2 trial. These patients had already been ...

A new first-in-class drug for use in the treatment of relapsed or refractory multiple myeloma looks to be a step closer to the market after a US Food and Drug Administration (FDA) advisory panel gave ...

The National Health Service (NHS) England is set to become the first health system globally to offer the "Trojan horse" therapy, belantamab mafodotin (Blenrep), developed by GSK, for patients with ...

Review the side-effects of Belantamab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination; benefit seen early and maintained through follow-up Data build on findings ...